Promises and limitations of mendelian randomization for evaluation of biomarkers

Clin Chem. 2010 Mar;56(3):388-90. doi: 10.1373/clinchem.2009.142513. Epub 2010 Jan 21.

Author

Robert J Glynn¹

Affiliation

¹ Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Ave., Boston, MA 02215, USA. rglynn@rics.bwh.harvard.edu

PMID: 20093553
DOI: 10.1373/clinchem.2009.142513

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers* / analysis
C-Reactive Protein*
Clinical Trials as Topic
Coronary Disease / diagnosis*
Humans
Mendelian Randomization Analysis*

Substances

Biomarkers
C-Reactive Protein